Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179407 · ClinicalTrials.gov registry record · Phase 1
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT06179407 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 9 participants.
The verdict
NCT06179407, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). The effect of single MK-6552 doses were assessed initially under open-label conditions to evaluate the safety, tolerability, and PK of MK-6552. The effect of repeated MK-6552 doses (every 8 hours \[q8h\] for 7 days) were assessed under double-blind and placebo-controlled conditions.
Interventions
- DRUG Placebo
- DRUG MK-6552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06179407
The ClinicalTrials.gov registry entry for NCT06179407 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06179407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06179407 about?
NCT06179407 is a clinical study titled "Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)". The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). The effect of single MK-6552 doses were assessed initially under open-label conditions to evaluate the safety, tolerability, and P...
What is the current status of trial NCT06179407?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2024-01-24. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT06179407?
The interventions under investigation include: Placebo (DRUG), MK-6552 (DRUG).
Who is sponsoring clinical trial NCT06179407?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.